Notícias25/11/2021 The N501Y spike substitution enhances SARS-CoV-2 infection and transmissionThe B.1.1.7 variant (also known as Alpha) of SARS-CoV-2, the cause of the COVID-19 pandemic, emerged in the UK in... Repositório Covid-19 23/11/2021 Bio-Manguinhos tem novo laboratório para controle de vacinasBio-Manguinhos tem novo laboratório para controle de vacinas. Unidade vai controlar a qualidade das vacinas e de outros produtos... Associado em foco 19/11/2021 Prati-Donaduzzi será a maior produtora de comprimidos da América LatinaPrati-Donaduzzi será a maior produtora de comprimidos da América Latina. Investimentos em tecnologia, PD&I e ampliações físicas ampliam em 40%... Associado em foco18/11/2021 Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialAspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate... Repositório Covid-1918/11/2021 Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineThe CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy... Repositório Covid-1918/11/2021 SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic caused by it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... Repositório Covid-1918/11/2021 Organ-specific genome diversity of replication-competent SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not always confined to the respiratory system, as it impacts people... Repositório Covid-1918/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%... Repositório Covid-1916/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method... Repositório Covid-1916/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread... Repositório Covid-1915/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This... Repositório Covid-1914/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute... Repositório Covid-19
25/11/2021 The N501Y spike substitution enhances SARS-CoV-2 infection and transmissionThe B.1.1.7 variant (also known as Alpha) of SARS-CoV-2, the cause of the COVID-19 pandemic, emerged in the UK in... Repositório Covid-19
23/11/2021 Bio-Manguinhos tem novo laboratório para controle de vacinasBio-Manguinhos tem novo laboratório para controle de vacinas. Unidade vai controlar a qualidade das vacinas e de outros produtos... Associado em foco
19/11/2021 Prati-Donaduzzi será a maior produtora de comprimidos da América LatinaPrati-Donaduzzi será a maior produtora de comprimidos da América Latina. Investimentos em tecnologia, PD&I e ampliações físicas ampliam em 40%... Associado em foco
18/11/2021 Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialAspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate... Repositório Covid-19
18/11/2021 Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineThe CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy... Repositório Covid-19
18/11/2021 SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic caused by it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... Repositório Covid-19
18/11/2021 Organ-specific genome diversity of replication-competent SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not always confined to the respiratory system, as it impacts people... Repositório Covid-19
18/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%... Repositório Covid-19
16/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method... Repositório Covid-19
16/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread... Repositório Covid-19
15/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This... Repositório Covid-19
14/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute... Repositório Covid-19